Evoke Pharma Partners with EVERSANA to Enhance GIMOTI Access
Evoke Pharma and EVERSANA Work Together to Expand GIMOTI Access
Evoke Pharma, Inc. (NASDAQ: EVOK), known for its innovations in gastroenterology treatments, has announced an exciting collaboration with EVERSANA. This partnership is aimed at improving the accessibility of GIMOTI, a unique nasal spray for adults suffering from diabetic gastroparesis, a condition affecting the stomach's ability to empty normally.
Strategic Collaboration with Omnicell
As part of this initiative, Evoke has secured a partnership with Omnicell, a leading company in medication management and fulfillment. This collaboration is set to enhance patient access to GIMOTI particularly within large gastroenterological practice networks.
Broadening Distribution Channels
By integrating with Omnicell’s extensive network of specialty pharmacies, which are trusted by gastroenterology professionals, Evoke aims to significantly widen the availability of GIMOTI. The goal is to facilitate smoother outreach to patients who require this vital treatment across various health centers.
Enhancing Patient Experience
Matt D’Onofrio, the CEO of Evoke Pharma, emphasizes the importance of this partnership, stating that aligning with specialty pharmacies will result in improved patient care and faster access to necessary treatments. This strategy reflects Evoke's commitment to ensuring that healthcare providers can focus more on patient care without barriers.
Understanding Large GI Practices
Large gastroenterology practices are structured to deliver efficient and scalable patient care. By leveraging the resources of Omnicell, Evoke Pharma ensures that these institutions have access to GIMOTI alongside their preferred specialty pharmacies. This means that gastroenterologists can provide their patients with GIMOTI as part of their treatment plans quickly and effectively.
New Heights with Brentwood Pharmacy
In addition to the Omnicell partnership, Evoke has successfully entered into an agreement with Brentwood Pharmacy, affiliated with OneGI, another significant player in the gastroenterology sector. This partnership further solidifies Evoke's efforts to streamline the distribution of GIMOTI, enhancing patient access and supporting a variety of insurance plans.
OneGI’s Role in the Expansion
OneGI has a substantial network of gastroenterologists, making it easier for Evoke to deploy GIMOTI efficiently across several states. With approximately 200 gastroenterologists under its umbrella, OneGI ensures that patients receive the care they need promptly.
About GIMOTI®
GIMOTI, a nasal spray formulation of metoclopramide, was developed specifically to address the symptoms associated with diabetic gastroparesis. This condition impacts millions worldwide, causing slow gastric emptying and leading to various health complications. It is noteworthy that prior to GIMOTI’s approval, metoclopramide was only available in oral and injectable forms.
Safeguards and Risks
While GIMOTI has been helpful for many, patients should be aware of potential risks involved with its use, including tardive dyskinesia, especially with prolonged usage. Evoke urges healthcare professionals to inform patients about these risks and monitor their treatment closely.
Mission and Vision
Evoke Pharma remains dedicated to crafting solutions that not only treat medical conditions but also enhance the overall quality of life for individuals dealing with gastrointestinal disorders. The collaboration with EVERSANA and other pharmacy networks is a testament to their commitment to innovation and patient-centered care.
Frequently Asked Questions
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide approved for the relief of symptoms in adults with diabetic gastroparesis.
How can I access GIMOTI?
Through partnerships with specialty pharmacies like Omnicell and Brentwood Pharmacy, GIMOTI is increasingly accessible to patients through various health centers and gastroenterology practices.
Who can use GIMOTI?
GIMOTI is intended for adults suffering from acute and recurrent diabetic gastroparesis, but there are contraindications, such as a history of tardive dyskinesia.
What is the role of EVERSANA in this collaboration?
EVERSANA provides commercial services that enhance the distribution and accessibility of pharmaceutical products, including GIMOTI, to ensure better patient experiences.
What are the potential side effects of GIMOTI?
Common side effects include dysgeusia, headache, fatigue, and more serious risks like tardive dyskinesia, which necessitates careful monitoring by healthcare providers.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.